Johnson & Johnson: Long-Acting Schizophrenia Treatment Has Been Approved by China's Drug Regulator to Enter the Market
強生公司:長效治療精神分裂症已獲得中國藥品監管機構的批准進入市場
Johnson & Johnson: Long-Acting Schizophrenia Treatment Has Been Approved by China's Drug Regulator to Enter the Market
強生公司:長效治療精神分裂症已獲得中國藥品監管機構的批准進入市場
譯文內容由第三人軟體翻譯。